Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131%
11:07am, Friday, 26'th Dec 2025
Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth.
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (th
Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's EBITDA by e
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript
04:22pm, Thursday, 11'th Dec 2025
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
02:00am, Thursday, 11'th Dec 2025
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2025 – Genmab A/S (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Da
Media Release COPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT)
Media Release COPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R 2 ) resulted in statistically significant and c
Media Release COPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE ® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in
AI Plays Lead Five Stocks To Watch Near Buy Points
08:00am, Saturday, 06'th Dec 2025
Taiwan Semiconductor leads three rebounding AI plays. Genmab and JPMorgan also are stocks to watch.
Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval
08:36am, Friday, 05'th Dec 2025
FDA approves Breyanzi, a CAR T cell therapy for relapsed or refractory marginal zone lymphoma. It has a high response rate.
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages
02:00am, Friday, 05'th Dec 2025
Shares of Genmab A/S Sponsored ADR (NASDAQ: GMAB - Get Free Report) have received an average rating of "Moderate Buy" from the eleven research firms that are covering the firm, MarketBeat Ratings repo
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
02:28pm, Thursday, 04'th Dec 2025
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes
03:03pm, Wednesday, 03'rd Dec 2025
Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have clos
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
04:24pm, Monday, 01'st Dec 2025
Company Announcement COPENHAGEN, Denmark; December 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/5
Genmab A/S Sponsored ADR $GMAB Shares Purchased by Creative Planning
04:03am, Saturday, 29'th Nov 2025
Creative Planning raised its stake in shares of Genmab A/S Sponsored ADR (NASDAQ: GMAB) by 11.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fun
